Overview

Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations

Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
Phase:
Phase 2
Details
Lead Sponsor:
Palvella Therapeutics, Inc.